Icandra Plus 50/1000 mg

Trade Name:

Icandra Plus 50 mg/1000 mg

Composition

Each tablet contains:

Vildagliptin 50 mg

Metformin hydrochloride 1000 mg

Inactive ingredients:

Microcrystalline cellulose, sodium croscarmellose, Povidone K30, Aerosil, magnesium stearate.

Properties

Combined hypoglycemic agent for oral administration.

Vildagliptin, a representative of the class of stimulators of the pancreatic insular apparatus, selectively inhibits the enzyme DPP-4, improving glycemic control. Inhibition of DPP-4 activity causes an increase in both basal and postprandial endogenous levels of incretin hormones: glucagon-like peptide type 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Metformin reduces glucose production by the liver, reduces glucose absorption in the intestine and reduces insulin resistance by increasing the uptake and utilization of glucose by peripheral tissues. Metformin induces intracellular glycogen synthesis by acting on glycogen synthetase, and enhances glucose transport by some glucose-carrying membrane proteins (GLUT-1 and GLUT-4). Improves glucose tolerance in patients with type 2 diabetes mellitus by reducing the concentration of glucose in blood plasma both before and after meals. Unlike sulfonylurea derivatives, metformin does not cause hypoglycemia either in patients with type 2 diabetes mellitus or in healthy individuals (except in special cases). Metformin does not lead to the development of hyperinsulinemia. When metformin is used, insulin secretion does not change, while the concentration of insulin in the blood plasma on an empty stomach and during the day may decrease.

Indications

Type 2 diabetes mellitus (in combination with diet therapy and physical exercises).

Method of administration and dosage:

The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

Contraindications

Type 1 diabetes mellitus; severe renal insufficiency or impaired renal function with GFR <30 ml/min; acute conditions with a risk of developing renal dysfunction: dehydration (with diarrhea, vomiting), fever, severe infectious

diseases, hypoxia conditions (shock, sepsis, kidney infections, bronchopulmonary diseases); acute and chronic heart failure, acute myocardial infarction, acute cardiovascular insufficiency (shock), respiratory failure; liver dysfunction; acute or chronic metabolic acidosis (including diabetic ketoacidosis in combination with coma or without it); lactic acidosis (including in the anamnesis); should not be used 48 hours before surgical operations, radioisotope, X-ray examinations with the introduction of contrast agents and within 48 hours after their implementation; chronic alcoholism, acute alcohol poisoning; compliance with a low-calorie diet (less than 1000 kcal / day); pregnancy, lactation (breast feeding); hypersensitivity to vildagliptin or metformin or any other components of the drug.

Warnings and precautions:

Side effects

From the nervous system: often — headache, dizziness, tremor. When using vildagliptin in combination with metformin in various doses, hypoglycemia was observed in 0.9% of cases (for comparison, in the placebo group in combination with metformin — in 0.4%).

From the digestive system: often — nausea, gastroesophageal reflux, dysgeusia; infrequently — diarrhea, flatulence; very rarely — hepatitis.

From the side of metabolism and nutrition: very often — decreased appetite; often — hypoglycemia; very rarely — lactic acidosis.

Storage

In a cool, dry place at a temperature not exceeding 30 °C.

Package:

A carton box contains 1.2 or 3 blisters of 10 tablets, paper leaflet.